Epitope peptide of COL1A1 and complex of said epitope peptide and heat shock protein

By preparing an epitope peptide of COL1A1 to form a complex with heat shock protein, and stimulating immune cells, the problem of inducing a specific immune response against tumor cells expressing COL1A1 in existing technologies has been solved, thus achieving effective treatment for tumors such as breast cancer and liver cancer.

CN115490768BActive Publication Date: 2024-11-15FOSHAN HEAT SHOCK BIOTECH CO LTD
View PDF 26 Cites 0 Cited by

Patent Information

Application Number
CN202110680153.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-06-18
Publication Date
2024-11-15
Estimated Expiration
2041-06-18

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively induce specific immune responses against tumor cells expressing COL1A1, resulting in poor treatment outcomes for tumors such as breast cancer and liver cancer.

Method used

By preparing a complex of COL1A1 epitope peptide with heat shock protein, this complex is used to stimulate immune cells, especially T cells, to induce their specific recognition and killing of tumor cells expressing COL1A1.

Benefits of technology

This complex can significantly enhance the immune system's ability to kill tumor cells expressing COL1A1, providing an effective means of prevention and treatment, including the preparation of tumor vaccines for the prevention or treatment of tumors expressing COL1A1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115490768B_ABST
    Figure CN115490768B_ABST
Patent Text Reader

Abstract

This invention relates to the fields of immunology and tumor therapy. Specifically, it relates to epitope peptides of protein COL1A1 and combinations thereof, specific immune cells induced by these peptides, tumor vaccines containing them, and their use for the prevention or treatment of tumors. The invention also relates to complexes formed by said epitope peptides and heat shock proteins, specific immune cells induced by these complexes, tumor vaccines containing them, and their use for the prevention or treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of immunology and tumor treatment. Specifically, the present invention relates to epitope peptides of protein COL1A1 and combinations thereof, specific immune cells induced therefrom, tumor vaccines containing them, and uses thereof for preventing or treating tumors. The present invention also relates to complexes formed by the epitope peptides and heat shock proteins, specific immune cells induced therefrom, tumor vaccines containing them, and uses thereof for preventing or treating tumors. Background Art

[0002] Breast cancer is one of the most common malignant tumors in women. According to statistics, the incidence of breast cancer accounts for 7-10% of all malignant tumors in the body. In many areas, it has exceeded uterine cancer and has become one of the most common tumors that seriously affects women's physical and mental health and even endangers their lives. The incidence of breast cancer is closely related to the patient's genetic genes, living habits, common food, fertility status, etc.

[0003] Liver cancer refers to malignant tumors occurring in the liver, including primary liver cancer and metastatic liver cancer. Primary liver cancer is one of the most common malignant tumors clinically.

[0004] Collagen alpha-1(I) chain (COL1A1) is an important component of type I collagenase, a fibrous collagen found in most connective tissues, and abundant in bone, cornea, dermis, and tendons. Translocation between chromosomes 17 and 22, where this gene and the platelet-derived growth factor gene are located, is associated with a special type of skin tumor, dermatofibrosarcoma protuberans, which is caused by unregulated expression of growth factors. At the same time, more and more studies have shown that COL1A1 plays a key role in the occurrence and development of tumors and promotes tumor metastasis. In high-incidence cancers such as liver cancer, lung cancer, and breast cancer, the expression of COL1A1 protein is significantly increased, and the expression level of COL1A1 is also directly related to the survival rate of cancer patients.

[0005] Heat shock protein (HSP) is a class of proteins that are highly conserved in biological evolution and widely present in prokaryotes and eukaryotes. HSP can be divided into multiple subfamilies such as HSP110, HSP90, HSP70, HSP60, HSP40, small molecule HSP and ubiquitin according to the degree of homology and molecular weight. Heat shock protein (HSP) gp96 belongs to the HSP90 subfamily. This protein is the most abundant heat shock protein on the endoplasmic reticulum of cells. Heat shock protein gp96 has polypeptide binding properties. In the endoplasmic reticulum, it can accept polypeptide fragments from the TAP complex, assist in assembling them into MHC class I molecules, and present them on the cell membrane. Heat shock protein gp96 from different tissue sources can carry polypeptide fragments specifically expressed in their source tissues. Summary of the invention

[0006] The present invention provides epitope peptides of protein COL1A1 and combinations thereof, and specific immune cells induced thereby. The present invention further provides a complex formed by the epitope peptide and heat shock protein, and specific immune cells induced thereby.

[0007] Therefore, in one aspect, the present invention provides an isolated polypeptide having an amino acid sequence as shown in SEQ ID NO: 1, 2 or 3.

[0008] In another aspect, the present invention provides a polypeptide composition, comprising any two or three polypeptides selected from the following: polypeptides shown in any one of SEQ ID NOs: 1, 2 and 3.

[0009] In certain embodiments, the polypeptide compositions contain the same or different ratios of polypeptides.

[0010] In certain embodiments, the polypeptide composition comprises a polypeptide as set forth in SEQ ID NO:1, a polypeptide as set forth in SEQ ID NO:2, and a polypeptide as set forth in SEQ ID NO:3.

[0011] In certain embodiments, the mass ratio of the polypeptide shown in SEQ ID NO: 1, the polypeptide shown in SEQ ID NO: 2, and the polypeptide shown in SEQ ID NO: 3 in the polypeptide composition is 1:1:1 to 5:1:1, or 1:1:1 to 1:5:1, or 1:1:1 to 1:1:5.

[0012] In certain embodiments, the mass ratio of the polypeptide shown in SEQ ID NO: 1, the polypeptide shown in SEQ ID NO: 2, and the polypeptide shown in SEQ ID NO: 3 in the polypeptide composition is 1:1:1, or 5:1:1, or 1:5:1, or 1:1:5.

[0013] In certain embodiments, the polypeptide composition contains the polypeptide shown in SEQ ID NO: 1, the polypeptide shown in SEQ ID NO: 2, and the polypeptide shown in SEQ ID NO: 3 in a ratio of 1:1:1.

[0014] In another aspect, the present invention provides a complex formed by the isolated polypeptide as described above or the polypeptide composition as described above and a heat shock protein.

[0015] In certain embodiments, the complex is formed by the isolated polypeptide or the polypeptide composition described above and a heat shock protein by natural adsorption or heat shock.

[0016] In certain embodiments, the complex is prepared by mixing the isolated polypeptide as described above or the polypeptide composition as described above with a heat shock protein in vitro. In certain embodiments, the mixing is performed at 40-80° C. (e.g., 40-70° C., 40-60° C., or 50-60° C.). In certain embodiments, the mixing is performed at 55° C.

[0017] In certain embodiments, the complex is prepared by contacting the isolated polypeptide as described above or the polypeptide composition as described above with a heat shock protein and placing the mixture at 55° C. for 10 min, and then at room temperature for 30 min.

[0018] In certain embodiments, the heat shock protein is selected from HSP70, HSP90, gp96, HSP110, and mutants or fusion proteins thereof.

[0019] In certain embodiments, the heat shock protein is gp96. In certain embodiments, the heat shock protein has an amino acid sequence as shown in SEQ ID NO:6.

[0020] In certain embodiments, the complex is prepared by mixing in vitro a polypeptide isolated as described above or a polypeptide composition as described above with a heat shock protein in the following mass ratio: 0.1:1 to 100:1 (e.g., 0.1:1 to 50:1, 0.1:1 to 10:1, 0.1:1 to 5:1, 0.1:1 to 1:1, 0.5:1 to 100:1, 0.5:1 to 50:1, 0.5:1 to 10:1, 0.5:1 to 5:1, 0.5:1 to 1:1, 1:1 to 100:1, 1:1 to 50:1, 1:1 to 10:1, 1:1 to 5:1), preferably 1:1, 10:1 or 100:1.

[0021] In certain embodiments, the complex is immunogenic and is capable of inducing a specific immune response against cells expressing COL1A1 (eg, tumor cells, such as breast cancer or liver cancer cells).

[0022] In another aspect, the present invention provides a composition comprising at least two (eg, two, three, four, five, or more) complexes as described above.

[0023] In certain embodiments, the heat shock proteins in the composition are the same or different.

[0024] In certain embodiments, the composition is immunogenic and is capable of inducing a specific immune response against cells expressing COL1A1 (eg, tumor cells, such as breast cancer or liver cancer cells).

[0025] In another aspect, the present invention provides a method for preparing the complex as described above, which comprises mixing the isolated polypeptide as described above or the polypeptide composition as described above with a heat shock protein.

[0026] In certain embodiments, the isolated polypeptide as described above or the polypeptide composition as described above forms a complex with a heat shock protein by natural adsorption or heat shock.

[0027] In certain embodiments, the complex is prepared by mixing the isolated polypeptide as described above or the polypeptide composition as described above with a heat shock protein in vitro. In certain embodiments, the mixing is performed at 40-80° C. (e.g., 40-70° C., 40-60° C., or 50-60° C.). In certain embodiments, the mixing is performed at 55° C.

[0028] In certain embodiments, the method comprises: contacting the polypeptide isolated as described above or the polypeptide composition as described above with a heat shock protein and placing the mixture at 55° C. for 10 min, and then placing the mixture at room temperature for 30 min.

[0029] In certain embodiments, the heat shock protein is selected from HSP70, HSP90, gp96, HSP110, and mutants or fusion proteins thereof.

[0030] In certain embodiments, the heat shock protein is gp96. In certain embodiments, the heat shock protein has an amino acid sequence as shown in SEQ ID NO:6.

[0031] In certain embodiments, the method comprises: mixing in vitro the isolated polypeptide as described above or the polypeptide composition as described above with a heat shock protein in the following mass ratio: 0.1:1 to 100:1 (e.g., 0.1:1 to 50:1, 0.1:1 to 10:1, 0.1:1 to 5:1, 0.1:1 to 1:1, 0.5:1 to 100:1, 0.5:1 to 50:1, 0.5:1 to 10:1, 0.5:1 to 5:1, 0.5:1 to 1:1, 1:1 to 100:1, 1:1 to 50:1, 1:1 to 10:1, 1:1 to 5:1), preferably 1:1, 10:1 or 100:1.

[0032] In certain embodiments, the complex is immunogenic and is capable of inducing a specific immune response against cells expressing COL1A1 (eg, tumor cells, such as breast cancer or liver cancer cells).

[0033] In another aspect, the present invention provides a T cell expressing a T cell receptor that can specifically recognize galectin 3 (COL1A1) or the isolated polypeptide as described above or the polypeptide composition as described above.

[0034] In certain embodiments, the T cells are obtained by stimulating immune cells with the complex as described above or the composition as described above. In certain embodiments, the immune cells comprise PBMC or T lymphocytes.

[0035] In certain embodiments, the stimulation further comprises the use of an immunostimulatory cytokine (eg, IL-2).

[0036] In certain embodiments, the T cell is a cytotoxic T lymphocyte.

[0037] In certain embodiments, the T cells are capable of specifically recognizing and killing cells expressing COL1A1 (eg, tumor cells, such as breast cancer cells or liver cancer cells).

[0038] In another aspect, the present invention provides a method for preparing a T cell as described above, the method comprising stimulating an immune cell using the complex as described above or the composition as described above. In certain embodiments, the immune cell comprises PBMC or T lymphocyte.

[0039] In certain embodiments, the stimulation further comprises the use of an immunostimulatory cytokine (eg, IL-2). In certain embodiments, the immunostimulatory cytokine is IL-2.

[0040] In another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated polypeptide as described above. In certain embodiments, the isolated polypeptide has an amino acid sequence as shown in SEQ ID NO: 1, 2 or 3.

[0041] In another aspect, the present invention provides a combination of isolated nucleic acid molecules, comprising a nucleotide sequence encoding a polypeptide composition as described above; the polypeptide composition comprises any two or three polypeptides selected from the following: polypeptides shown in any one of SEQ ID NOs: 1, 2, and 3. In certain embodiments, the polypeptide composition comprises a polypeptide shown in SEQ ID NO: 1, a polypeptide shown in SEQ ID NO: 2, and a polypeptide shown in SEQ ID NO: 3.

[0042] In another aspect, the present invention provides a vector comprising an isolated nucleic acid molecule as described above or a combination of isolated nucleic acid molecules as described above.

[0043] In certain embodiments, the vector comprises a nucleotide sequence encoding an isolated polypeptide as described above or a polypeptide composition as described above.

[0044] In certain embodiments, the vector is a viral vector, such as a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, or a baculoviral vector.

[0045] In another aspect, the present invention provides a host cell comprising an isolated nucleic acid molecule as described above or a combination of isolated nucleic acid molecules as described above or a vector as described above.

[0046] In another aspect, the present invention provides a pharmaceutical composition comprising an isolated polypeptide as described above, a polypeptide composition as described above, a complex as described above, a composition as described above, a T cell as described above, an isolated nucleic acid molecule as described above, a combination of isolated nucleic acid molecules as described above, a vector as described above, or a host cell as described above, and a pharmaceutically acceptable carrier and / or excipient.

[0047] In certain embodiments, the pharmaceutical composition is a tumor vaccine.

[0048] In certain embodiments, the pharmaceutical composition comprises an adjuvant.

[0049] In certain embodiments, the pharmaceutical composition further comprises an additional therapeutic agent, such as an anti-tumor agent or an immune enhancing agent.

[0050] In certain embodiments, the anti-tumor agent is selected from an alkylating agent, a mitotic inhibitor, an anti-tumor antibiotic, an antimetabolite, a topoisomerase inhibitor, a tyrosine kinase inhibitor, a radionuclide agent, a radiosensitizer, an anti-angiogenic agent, a cytokine, an immune checkpoint inhibitor (e.g., a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody, a LAG-3 antibody, or a TIM3 antibody).

[0051] In certain embodiments, the immune enhancer is selected from an immunostimulatory antibody (e.g., an anti-CD3 antibody, an anti-CD28 antibody, an anti-CD40L (CD154) antibody, an anti-41BB (CD137) antibody, an anti-OX40 antibody, an anti-GITR antibody, or any combination thereof) or an immunostimulatory cytokine (e.g., IL-2).

[0052] In another aspect, the present invention provides use of the isolated polypeptide as described above, or the polypeptide composition as described above, or the complex as described above, or the composition as described above, or the T cell as described above in the preparation of a medicament for inducing an immune response against a tumor expressing COL1A1 in a subject, and / or preventing or treating a tumor expressing COL1A1 in a subject.

[0053] In certain embodiments, the tumor expressing COL1A1 is selected from colorectal cancer, pancreatic cancer, gastric cancer, lung cancer, endometrial cancer, ovarian cancer, multiple myeloma, melanoma, thyroid cancer, bladder cancer, prostate cancer, breast cancer, head and neck cancer, or acute myeloid leukemia.

[0054] In certain embodiments, the T cells are from the subject.

[0055] In certain embodiments, the subject is a human.

[0056] In certain embodiments, the subject is HLA-A2 positive.

[0057] In certain embodiments, the isolated polypeptide, polypeptide composition, composition or T cell is administered in combination with another therapeutic agent, such as simultaneously, separately or sequentially. In certain embodiments, the other therapeutic agent is an immunostimulant or an anti-tumor agent.

[0058] In certain embodiments, the COL1A1 protein is abnormally expressed in the COL1A1-expressing tumor (eg, increased expression compared to healthy subjects).

[0059] In another aspect, the present invention provides a method for inducing an immune response against a tumor expressing COL1A1 in a subject, and / or preventing or treating a tumor expressing COL1A1 in a subject, the method comprising administering to a subject in need thereof an effective amount of the isolated polypeptide as described above, the polypeptide composition as described above, the complex as described above, the composition as described above, the T cell as described above, the nucleic acid molecule or vector or host cell comprising a nucleotide sequence encoding the isolated polypeptide or polypeptide composition, or the pharmaceutical composition as described above.

[0060] In certain embodiments, the tumor expressing COL1A1 is selected from colorectal cancer, pancreatic cancer, gastric cancer, lung cancer, endometrial cancer, ovarian cancer, multiple myeloma, melanoma, thyroid cancer, bladder cancer, prostate cancer, breast cancer, head and neck cancer, or acute myeloid leukemia. In certain embodiments, the subject is a human.

[0061] In certain embodiments, the subject is HLA-A2 positive.

[0062] In certain embodiments, the method further comprises administering to the subject an additional therapeutic agent, such as an immune enhancing agent or an anti-tumor agent.

[0063] In certain embodiments, the COL1A1 protein is abnormally expressed in the COL1A1-expressing tumor (eg, increased expression compared to healthy subjects).

[0064] In certain embodiments, the method comprises: (1) providing immune cells (e.g., PBMCs or T cells) from a subject; (2) contacting the complex or composition with the immune cells to obtain T cells as described above; (3) administering the T cells obtained in step (2) to the subject.

[0065] Definition of terms

[0066] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the virology, biochemistry, and immunology laboratory operation steps used herein are conventional steps widely used in the corresponding fields. At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0067] As used herein, the term "COL1A1" is also known as alpha-1 collagen. It is a component of type 1 collagen. The expression level of COL1A1 is regulated by multiple mechanisms, including mRNA stability, translation, and post-translational modification. The expression level of COL1A1 is associated with tumor development in gastric cancer, lung cancer, thyroid cancer, and breast cancer. Studies have shown that upregulation of COL1A1 can produce an improved extracellular matrix environment, promoting cancer cell survival, proliferation, metastasis, and invasion. COL1A1 is well known to those skilled in the art, and its sequence can be found in various public databases, such as the NCBI GENBANK database.

[0068] As used herein, the term "gp96" is also known as Grp94, which is a member of the heat shock protein 90 family located on the endoplasmic reticulum membrane of cells. The gp96 protein consists of an N-terminal domain (N-terminal ATP binding domain), an M domain (charged middle domain), and a C-terminal domain (C-terminal homodimerization domain). gp96 is well known to those skilled in the art, and its sequence can be found in various public databases, such as NCBI GENBANK database accession number: AAH66656.1.

[0069] As used herein, the term "HSP70" is a heat shock protein with a molecular weight of about 70 kDa, an important member of the heat shock protein family, known as the major heat shock protein, including more than 20 proteins with molecular weights of 68, 72, 73, 75, 78 kDa, etc. The HSP70 family proteins have similar molecular weights, isoelectric points between pH 5.2-6.3 and similar trypsin peptide spectra, are often highly induced in stressed cells of almost all organisms, and have the function of protecting the body and cells.

[0070] As used herein, the term "HSP90" is a heat shock protein with a molecular weight of about 90 kDa, and is a protein used for synergistic immunity. It is an important member of the heat shock protein family, and its molecular weight is about 83-90 kDa.

[0071] As used herein, the term "HSP110" is a heat shock protein with a molecular weight of about 110 kDa, and is an important member of the heat shock protein family, with a molecular weight of about 100-110 kDa.

[0072] As used herein, the term "isolated" or "isolated" refers to that obtained from the natural state by artificial means. If a certain "isolated" substance or component appears in nature, it may be that the natural environment in which it is located has changed, or the substance has been separated from the natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity separated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.

[0073] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site.

[0074] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0075] As used herein, the term "subject" includes, but is not limited to, various animals, particularly mammals, such as humans. In certain embodiments, the subject (eg, human) suffers from an autoimmune disease.

[0076] As used herein, the term "immune cell" refers to any cell of the immune system with one or more effector functions. Immune cells typically include cells that play a role in immune responses, and they generally have hematopoietic origins. The term "effector function" refers to the specialized functions of immune cells, such as enhancing or promoting the function or reaction of immune attack on target cells (such as killing of target cells, or inhibiting their growth or proliferation). For example, the effector function of T cells, for example, can be cytolytic activity or auxiliary or include the activity of secretion of cytokines. Examples of immune cells include T cells (such as α / βT cells and γ / δT cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells and bone marrow derived macrophages, etc.

[0077] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with a subject and an active ingredient, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH regulators, surfactants, ionic strength enhancers, agents that maintain osmotic pressure, agents that delay absorption, diluents, adjuvants, preservatives, stabilizers, and the like. For example, pH regulators include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol), and the like. Adjuvants include, but are not limited to, aluminum adjuvants (e.g., aluminum hydroxide), Freund's adjuvants (e.g., complete Freund's adjuvant), etc. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, etc. Stabilizers have the meanings generally understood by those skilled in the art, and are capable of stabilizing the desired activity of the active ingredient in the drug (e.g., inhibitory activity on PSD-95 ubiquitination), including, but not limited to, sodium glutamate, gelatin, SPGA, sugars (e.g., sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (e.g., glutamic acid, glycine), proteins (e.g., dried whey, albumin, or casein) or their degradation products (e.g., lactalbumin hydrolyzate), etc.

[0078] As used herein, the term "treating" refers to treating or curing a disease (eg, an autoimmune disease), delaying the onset of one or more symptoms of a disease, and / or delaying the progression of a disease.

[0079] As used herein, the term "effective amount" refers to an amount that can effectively achieve the intended purpose. For example, a therapeutically effective amount can be an amount that is effective or sufficient to treat or cure a disease (e.g., an autoimmune disease), delay the onset of one or more symptoms of a disease, and / or delay the development of a disease. Such an effective amount can be easily determined by a person skilled in the art or a doctor, and can be related to the intended purpose, the general health of the subject, age, sex, body weight, severity of the disease to be treated, complications, mode of administration, etc. The determination of such an effective amount is completely within the capabilities of those skilled in the art.

[0080] Beneficial Effects

[0081] The complex of the three polypeptides of the protein COL1A1 of the present invention or their combination and the heat shock protein is immunogenic and can induce a specific immune response against cells expressing COL1A1 (e.g., tumor cells, such as breast cancer cells or liver cancer cells). Further, the complex can induce the production of specific immune cells, which can kill tumor cells expressing COL1A1, thereby preventing or treating tumors expressing COL1A1. In addition, the three polypeptides of the protein COL1A1 and their combination can be used to prepare tumor vaccines, which can be used to prevent or treat tumors expressing COL1A1.

[0082] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be appreciated by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1 The results of SDS-PAGE and Western Blot analysis of gp96 expressed by insects in Example 1 of the present invention are shown.

[0084] Figure 2 The results are as follows: the killing results of breast cancer cells by specific CTL activated after the three polypeptides and mixed polypeptides in different ratios in Example 2 of the present invention were combined with gp96.

[0085] Figure 3The results are as follows: the killing effects of the three polypeptides in Example 2 of the present invention mixed in equal proportions and then complexed with gp96 on MCF-7 cells and T2 cells co-incubated with the three polypeptides by the activated specific CTL and the control group (human T cells stimulated by gp96).

[0086] Figure 4 The results are as follows: the killing results of MCF-7 cells by specific CTL activated after the three polypeptides and mixed polypeptides in different ratios in Example 4 of the present invention were combined with gp96.

[0087] Figure 5 This is the effect of the specific T cells induced by the reinfusion of the polypeptide-gp96 complex and the control group (gp96-stimulated human T cells) on the tumor volume of breast cancer in Example 3 of the present invention.

[0088] Figure 6 The results are as follows: the killing of human liver cancer cells and T2 cells co-incubated with the three polypeptides in Example 4 of the present invention by specific CTL activated after being mixed in equal proportions with gp96 and a control group (human T cells stimulated by gp96).

[0089] Figure 7 This is the effect of the specific T cells induced by the reinfusion of the polypeptide-gp96 complex and the control group (gp96-stimulated human T cells) on the volume of liver cancer tumors in Example 5 of the present invention.

[0090] Sequence information

[0091] Table 1: Information on the sequences involved in this application is described in the table below.

[0092]

[0093]

[0094] DETAILED DESCRIPTION

[0095] The invention will now be described with reference to the following examples which are intended to illustrate the invention rather than to limit the invention.

[0096] Those skilled in the art will appreciate that the embodiments describe the present invention by way of example and are not intended to limit the scope of protection claimed in the present application. The experimental methods in the embodiments are conventional methods unless otherwise specified. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially. The quantitative experiments in the embodiments were repeated three times, and the results were averaged.

[0097] The sources of the experimental materials involved in the following examples are as follows:

[0098] Nude mice were produced by Beijing Weitonglihua Experimental Animal Co., Ltd., and are referred to as mice in the examples. Peptides were synthesized by Shanghai Jier Biochemical Co., Ltd.

[0099] HepG2 cells (human hepatoma cells) were purchased from ATCC (American Type Culture Collection), catalog number HB-8065 TM .

[0100] MCF-7 cells (human breast cancer cells) were purchased from ATCC, catalog number

[0101] HTB-22 TM Sf9 cells are products of Invitrogen, with a catalog number of 11496-015.

[0102] Cellfectin II reagent is a product of Life technologies, with the catalog number being 10362-100.

[0103] Plasmid pFastBac TM 1 is a product of Invitrogen, catalog number 10359-016.

[0104] The gp96 monoclonal antibody was a product of Santa Cruz Company, with the catalog number of sc-56399.

[0105] The horseradish peroxidase-labeled goat anti-rat monoclonal antibody was a product of Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., with the catalog number of ZB-2307.

[0106] HiTrap-Q Sepharose ion exchange chromatography column is a product of GE Company, and the product catalog number is 17-5053-01.

[0107] Superdex 200 10 / 300GL molecular sieve chromatography column is a product of GE Company, and the product catalog number is 17517501.

[0108] Escherichia coli DH10Bac competent cells are a product of Beijing Yuanpinghao Biotechnology Co., Ltd., with a product catalog number of CL108-01.

[0109] Insect-XPRESSTM Protein-free Insect Cells medium with L-Glutamine is a product of LONZA, and the product catalog number is 12-730Q.

[0110] BSA, PMSF, NaHCO3, MnCl2, CaCl2, NaCl2, Tris, and methyl α-D-mannopyranoside are all products of Sigma-Aldrich, with product catalog numbers of V900933, P7626, 792519, V900197, 793639, 746398, T1378, and M6882, respectively.

[0111] Solution A: solute is 1 mM PMSF and 30 mM NaHCO3; solvent is distilled water; pH value is 7.4.

[0112] Solution B: Solutes are 2 mM MnCl2, 2 mM CaCl2, 500 mM NaCl and 1 mM PMSF; the solvent is pH 7.4, 20 mM Tris-HCl buffer.

[0113] Solution C: the solute is 10% (mass volume ratio) methyl α-D-mannopyranoside, 500 mM NaCl and 1 mM PMSF; the solvent is pH 7.4, 20 mM Tris-HCl buffer.

[0114] Cleaning solution: Dilute solution B to 10 times its volume with distilled water.

[0115] The Con A agarose gel column is a product of GE, with a product catalog number of 17-0440-01. The column has a size of 1.6×2.5 cm and is filled with Con A-Sepharose 4B.

[0116] The Hitrap Q anion exchange column is a product of GE Company, with the product catalog number of 17-1153-01. The specification of the column is 0.7×2.5 cm.

[0117] The HRP-labeled IgG antibody is a product of SEROTEC, with the catalog number of STAR117P.

[0118] The 1× washing solution is a 0.01 mol / L PBS buffer at pH 7.4 containing 0.1% (volume percentage) Triton-X100.

[0119] The 50 kD and 3 kD ultrafiltration tubes are products of Merck Millipore, with catalog numbers UFC905096 and UFC500324, respectively.

[0120] Example 1: Expression of recombinant gp96 protein using insect cells

[0121] 1. Recombinant plasmid pFastBac TM 1- Construction of gp96

[0122] 1. The RNA of HepG2 cells was extracted by Trizol method, and then reverse transcribed to obtain cDNA.

[0123] 2. Based on the nucleotide sequence of human gp96 gene (GenBank No. AY040226.1), primers F1 (SEQ ID NO: 4) and R1 (SEQ ID NO: 5) were chemically synthesized, which carry the recognition sequences of restriction endonucleases EcoRⅠ and XbaⅠ, respectively.

[0124] 3. After completing steps 1 and 2, PCR amplification is performed using the cDNA obtained in step 1 as a template and F1 and R1 synthesized in step 2 as primers to obtain a PCR amplification product containing a nucleotide sequence encoding heat shock protein gp96.

[0125] 4. Double digest the PCR amplification product with restriction endonucleases EcoRⅠ and XbaⅠ, and recover the digestion product.

[0126] 5. Cut the plasmid pFastBac with restriction endonucleases EcoRⅠ and XbaⅠ TM 1. Recover the vector backbone of about 4700 bp.

[0127] 6. Connect the enzyme cleavage product to the vector backbone to obtain a connection product.

[0128] 7. The ligation product obtained in step 6 was transformed into E. coli DH10Bac competent cells to obtain recombinant E. coli, and then the plasmid of the recombinant E. coli was extracted to obtain the recombinant plasmid pFastBac1-gp96. The recombinant plasmid pFastBac1-gp96 expresses the recombinant heat shock protein gp96 (hereinafter referred to as rgp96), and the amino acid sequence of rgp96 is shown in SEQ ID NO:6.

[0129] 2. Expression of rgp96

[0130] 1. Co-transfect Sf9 cells (1×10 6 Each Sf9 cell was transfected with approximately 4 μg of the recombinant plasmid pFastBac1-gp96; during the co-transfection process, the transfection reagent was Cellfectin II reagent, the culture medium was Insect-XPRESSTM Protein-free Insect Cells medium with L-Glutamine, incubated at 27°C for 72 h, and centrifuged. The supernatant was the P1 generation virus.

[0131] 2. Sf9 cell suspension 1 (containing 1×10 8Sf9 cells) were cultured at 27° C. for 8 to 10 hours to obtain cultured cells; then, P1 virus (at a dosage of 0.05 to 0.1 MOI) was added to the cultured cells, incubated at 27° C. for 72 hours, and centrifuged at 4000 rpm for 5 minutes. The supernatant was the P2 virus.

[0132] 3. Add Sf9 cell suspension 2 (containing 1.6×10 8 P2 virus (at a dose of 0.05-0.1 MOI) was added to each Sf9 cell), cultured at 27°C and 100-120 rpm for 72 h, and centrifuged at 4000 rpm for 5 min. The supernatant was the P3 virus.

[0133] Using anti-gp96 monoclonal antibody as primary antibody and horseradish peroxidase-labeled goat anti-rat monoclonal antibody as secondary antibody, SDS-PAGE and Western blot hybridization were performed on the P3 virus. The specific steps of Western blot hybridization are as follows: Zhang Yueming, Duan Yueqiang, Luo Deyan, Yao Huijuan, Wang Xiliang, Li Zhikui. Expression and identification of mouse soluble IL-5α receptor in Bac-to-Bac system [J]. Chinese Journal of Biological Products, 2013, 26: 5. The results of SDS-PAGE and Western Blot hybridization showed that rgp96 protein was successfully expressed in Sf9 cells.

[0134] 3. Purification of rgp96 protein

[0135] 1. Add 300 ml of Sf9 cell suspension 3 (containing 4.5×10 8 P3 virus (at a dose of 5 MOI) was added to each Sf9 cell) and cultured at 27° C. and 100-120 rpm for 72 h to obtain a suspension.

[0136] 2. Take the suspension, centrifuge at 7000 rpm for 20 min, and obtain supernatant 1.

[0137] 3. Take the supernatant 1 and filter it through a 0.22 mm filter membrane to obtain a sample solution.

[0138] 4. The sample solution was loaded onto a HiTrap-Q Sepharose ion exchange chromatography column (flow rate of 1 mL / min), and then rinsed with 5 mL of pH 7.5, 200 mM PBS buffer (flow rate of 1 mL / min); then rinsed with 10 mL of pH 7.5, 300 mM PBS buffer (flow rate of 1 mL / min); and finally rinsed with 3 mL of pH 7.5, 600 mM PBS buffer (flow rate of 1 mL / min), and the solution after the column was collected and ultrafiltered and concentrated using an ultrafiltration tube with a molecular weight cutoff of 50 KD to obtain a concentrate of about 1 mL. The concentrate contains rgp96.

[0139] 5. The concentrated solution obtained in step 4 was loaded onto a Superdex 200 10 / 300GL molecular sieve chromatography column (flow rate of 0.25 mL / min), then washed with pH 7.5, 150 mM PBS buffer (flow rate of 0.25 mL / min), and the flowthrough at 9 to 12 mL was collected, and further ultrafiltration and concentration were performed using an ultrafiltration tube with a molecular weight cutoff of 50 KD to obtain a solution of rgp96. The protein concentration in the rgp96 solution was determined by the BCA method, and finally packaged and stored at -80°C.

[0140] The rgp96 solution obtained in step 5 was subjected to SDS-PAGE electrophoresis analysis and Western blot hybridization (anti-gp96 monoclonal antibody was used as the primary antibody and horseradish peroxidase-labeled goat anti-rat monoclonal antibody was used as the secondary antibody). Figure 1 As shown, lane 1 is a high molecular weight standard protein Marker, lane 2 is the SDS-PAGE electrophoresis result of rgp96, and lane 3 is the Western blot hybridization result of rgp96. Figure 1 The results showed that the rgp96 solution showed a single molecular weight band (as indicated by the arrow), and the corresponding molecular weight was consistent with the expected value, that is, after the steps in step three above, rgp96 was effectively expressed and purified.

[0141] Example 2: Cytotoxic effect of specific CTL induced by polypeptide-gp96 complex on human breast cancer cells

[0142] 1. Preparation of peptide-gp96 complex

[0143] The polypeptides shown in SEQ ID NO: 1-3 were chemically synthesized respectively, and each polypeptide was prepared into a polypeptide solution with a concentration of 20 mg / mL using DMSO. 1 mg of each polypeptide was taken and mixed with 1 mg, 0.1 mg, and 0.01 mg of heat shock protein gp96, respectively, and dissolved in pH 7.4 0.01 mol / L PBS buffer to a total volume of 4 mL, and then heat-shocked at 55° C. for 10 minutes, cooled at room temperature for 30 minutes, and finally washed away with a 50 kD ultrafiltration tube to remove unbound polypeptides, thereby obtaining gp96-polypeptide complexes formed by each polypeptide and gp96 of different masses, a total of 9 kinds, as shown in Table 2 below.

[0144] Table 2. Peptide-gp96 complex

[0145] Compound name Peptides used Mass ratio of peptide to gp96 Peptide 1-1 SEQ ID NO:1 1:1 Peptide 1-0.1 SEQ ID NO:1 10:1 Peptide 1-0.01 SEQ ID NO:1 100:1 Peptide 2-1 SEQ ID NO:2 1:1 Peptide 2-0.1 SEQ ID NO:2 10:1 Peptide 2-0.01 SEQ ID NO:2 100:1 Peptide 3-1 SEQ ID NO:3 1:1 Peptide 3-0.1 SEQ ID NO:3 10:1 Peptide 3-0.01 SEQ ID NO:3 100:1

[0146] The three polypeptides shown in SEQ ID NO: 1-3 were mixed in 4 different mass ratios (the specific ratios are shown in Table 3), and DMSO was used to prepare a polypeptide mixed solution with a concentration of 20 mg / mL. For each mixed polypeptide solution, a mixed solution containing 1 mg of polypeptide was taken, and each mixed polypeptide solution was mixed with 1 mg, 0.1 mg, and 0.01 mg of heat shock protein gp96, respectively, and dissolved with pH 7.4 0.01 mol / L PBS buffer to a total volume of 4 mL, and then heat-shocked at 55° C. for 10 minutes, cooled at room temperature for 30 minutes, and finally washed away with a 50 kD ultrafiltration tube to remove unbound polypeptides, thereby obtaining 4 mixed polypeptides with different mixing ratios and gp96 of different masses to form gp96-polypeptide complexes, a total of 12 types, as shown in Table 3 below.

[0147] Table 3. Peptide-gp96 complex

[0148]

[0149]

[0150] 2. Preparation of human tumor-specific effector cells

[0151] 1. Anticoagulated fresh whole blood from HLA-A2 positive volunteers was separated using human lymphocyte separation medium (purchased from Cellgro, catalog number: 25-072-CI) to obtain peripheral blood mononuclear cells (PBMCs), and the cell concentration was adjusted to 1.0×10 with RPMI-1640 complete medium (purchased from Gibco, catalog number: 12633012) containing 10% fetal bovine serum (purchased from Gibco, catalog number: 10099-141-FBS). 6 / mL, inoculated in 24-well plates, 1mL per well.

[0152] 2. The next day, the polypeptide-gp96 complex prepared above was added to each group to a final concentration of 10 μg / mL, and a group with gp96 protein alone was added as a negative control.

[0153] 3. On the third day, add IL-2 (purchased from PeproTech, catalog number: 212-12) to each well to a final concentration of 50 U / mL. Replace half of the medium every 2-3 days and supplement IL-2 to a final concentration of 50 U / ml.

[0154] 4. The second and third rounds of peptide-gp96 complex / gp96 stimulation were performed on the seventh and fourteenth days, respectively, and IL-2 was added to a final concentration of 50 U / ml the next day.

[0155] 5. Three days after the third round of stimulation, effector cells CTL were obtained.

[0156] 3. Detection of specific killing effect of breast cancer cells

[0157] Target cells used for detection: human breast cancer cell line MCF-7 (HLA-A2 positive), T2 cells (HLA-A2 positive) incubated with three polypeptides in a mass ratio of 1:1:1, and the incubated T2 cells presenting the polypeptides.

[0158] use Non-radioactive cytotoxicity assay (purchased from Promega, catalog number: G1780) was used to detect cytotoxic activity. The main steps are as follows (see the kit instructions for details):

[0159] 1. Experimental group: MCF-7 cells and T2 cells incubated with three peptides at a mass ratio of 1:1:1 were used as target cells. The number of inoculated target cells was 5×10 3 / well, the above effector cells were added at a ratio of 5:1, 10:1 or 20:1, and the effector cells were inoculated in a 96-well culture plate at 50 μL / well, with a final volume of 100 μL.

[0160] In addition, a spontaneous LDH release group of effector cells was set up to calibrate the spontaneous LDH release of effector cells (50 μL / well of effector cells in each group was added to a 96-well plate, and 50 μL of RPMI-1640 medium containing 5% fetal bovine serum was supplemented to a final volume of 100 μL). A spontaneous LDH release group of target cells was used to calibrate the spontaneous LDH release of target cells (50 μl / well of target cells in each group was added to a 96-well plate, and 50 μL of RPMI-1640 medium containing 5% fetal bovine serum was supplemented to a final concentration of 100 μL). A maximum LDH release group of target cells was used as a reference for determining 100% LDH release during calculation (cell loading was the same as the spontaneous release group of target cells). A volume correction control group was used to correct the volume change caused by the addition of lysate (100 μL of RPMI-1640 medium containing 5% fetal bovine serum was added). The culture medium background control group was used to correct the LDH activity produced by the serum in the culture medium and the background absorption caused by phenol red (100 μL of RPMI-1640 culture medium containing 5% fetal bovine serum was added).

[0161] 2. After cell inoculation, centrifuge at 250g for 4 minutes, and then incubate in a 37°C incubator for 4 hours; 45 minutes before harvesting the supernatant, add lysis buffer (10×) to the target cell maximum LDH release group, 10 μL / well; then centrifuge at 250g for 4 minutes and harvest the supernatant.

[0162] 3. Transfer 50 μl of supernatant to the ELISA plate, prepare the substrate with detection buffer, add 50 μl / well of the prepared substrate to the ELISA plate, cover the plate, react at room temperature in the dark for 30 minutes, add 50 μL of stop solution to each well, and detect the absorbance OD at 490 nm in an ELISA reader within 1 hour.

[0163] 4. Calculation of cell killing rate

[0164] Killing rate (%) = [(OD value of experimental group - OD value of effector cell spontaneous release group - OD value of target cell spontaneous release group) / (OD value of target cell maximum release group - OD value of target cell spontaneous release group)] × 100%

[0165] The experimental results are as follows Figure 2 As shown, under the condition of an effector-target ratio of 20:1, the CTL activated by 21 complexes of polypeptides and gp96 all have tumor killing activity, while the control without polypeptide (containing only gp96) kills less than 7% of tumor cells. The killing efficiency of CTL activated by the three polypeptides mixed in a mass ratio of 1:1:1 and complexed with gp96 is as high as 20%-60% for tumor cells; and the killing efficiency of CTL activated by mixing the polypeptide mixture with gp96 in a mass ratio of 1:1 is as high as 45%-60%. In summary, the killing efficiency of CTL activated by mixing the three polypeptides themselves in equal proportions and compounding the mixture with gp96 in equal proportions is the highest. Among them, under the condition of an effector-target ratio of 5:1, 10:1 or 20:1, the killing results of CTL activated by the three polypeptides themselves in equal proportions and compounding the mixture with gp96 in equal mass ratios (such as the complex shown in Mixture 1-1 in Table 3) for tumor cells are as follows Figure 3 As shown, the results showed that CTL activated by the three polypeptide-gp96 complexes had a significant killing effect on pancreatic cancer cells, while CTL activated by gp96 as a control group had almost no killing activity.

[0166] Example 3: Therapeutic effect of specific CTL induced by polypeptide-gp96 complex on breast cancer

[0167] Twenty female nude mice aged 6-8 weeks were selected and 10 7 Specific T cells induced by peptide-gp96 complexes (0.5 mL), the peptide-gp96 complex is a complex formed by mixing three peptides in equal proportions and compounding with gp96 in equal mass proportions (such as the complex shown in Mix 1-1 in Table 3); 3 days after the reinfusion, all mice were subcutaneously inoculated with 5×10 6 MCF-7 liver cancer cells; On the second day after tumor inoculation, the mice were divided into two groups, 10 mice in each group, and treated as follows:

[0168] Group 1: Human T lymphocytes activated by peptide-gp96 complex were infused into the tail vein for three immunizations (0.5 mL each time), with a single infusion dose of 10 7 Piece / piece;

[0169] Group 2: gp96-stimulated human T cells were infused into the tail vein for three immunizations (0.5 mL each time), with a single immunization dose of 10 7 Piece / piece;

[0170] In the above two groups, the tumor cells were infused three times on the 2nd, 3rd, and 4th days after inoculation. Starting from the first day of infusion, the tumor growth was observed every day, the tumor size was recorded, and the tumor volume was calculated according to the following formula: V = ab 2 / 2 (V—volume, a—long diameter of tumor, b—short diameter of tumor). Changes in tumor volume can be seen in Figure 4 The results showed that CTLs induced by the three peptide-gp96 complexes could significantly inhibit the growth of breast cancer tumors.

[0171] Example 4: Cytotoxic effect of specific CTL induced by polypeptide-gp96 complex on human liver cancer cells

[0172] 1. Preparation of polypeptide-gp96 complex is the same as in Example 2

[0173] II. Preparation of human tumor-specific effector cells See Example 2

[0174] 3. Detection of specific killing effect on liver cancer cells

[0175] The target cells used for detection were: human liver cancer cell HEPG2 (HLA-A2 positive), T2 cells (HLA-A2 positive) incubated with the three polypeptides in a mass ratio of 1:1:1, and the incubated T2 cells presented the polypeptides.

[0176] The detection method was the same as in Example 2. The experimental group was added with effector cells and target cells at a corresponding ratio of 5:1, 10:1 or 20:1. At the same time, the effector cell spontaneous release group, target cell spontaneous release group, target cell maximum release group, background control group, and volume correction control group were set up. After incubation at 37°C for 4 hours, cell lysis buffer was added and the supernatant was harvested for LDH detection.

[0177] The experimental results are as follows Figure 5As shown, under the condition of an effector-target ratio of 20:1, CTLs activated by 21 complexes of polypeptides and gp96 all have tumor killing activity, while the control without polypeptide (containing only gp96) kills less than 7% of tumor cells. The killing efficiency of CTL activated by the three polypeptides mixed in a mass ratio of 1:1:1 and complexed with gp96 is as high as 20%-60% for tumor cells; and the killing efficiency of CTL activated by mixing the polypeptide mixture with gp96 in a mass ratio of 1:1 is as high as 40%-60%. In summary, the killing efficiency of CTL activated by mixing the three polypeptides themselves in equal proportions and compounding the mixture with gp96 in equal proportions is the highest. Among them, under the condition of an effector-target ratio of 5:1, 10:1 or 20:1, the killing results of CTL activated by the three polypeptides themselves in equal proportions and compounding the mixture with gp96 in equal mass ratios (such as the complex shown in Mixture 1-1 in Table 3) for tumor cells are as follows Figure 6 As shown, the results showed that CTL activated by the three polypeptide-gp96 complexes had a significant killing effect on liver cancer cells, while CTL activated by gp96 as a control group had basically no killing activity.

[0178] Example 5: Therapeutic effect of specific CTL induced by polypeptide-gp96 complex on liver cancer model

[0179] Twenty female nude mice aged 6-8 weeks were selected and 10 7 Specific T cells induced by peptide-gp96 complexes (0.5 mL), the peptide-gp96 complex is a complex formed by mixing three peptides in equal proportions and combining them with gp96 in equal mass proportions; 3 days after the reinfusion, all mice were subcutaneously inoculated with 5×10 6 HEPG2 liver cancer cells; On the second day after tumor inoculation, the mice were divided into two groups, 10 mice in each group, and treated as follows:

[0180] Group 1: Human T lymphocytes activated by peptide-gp96 complex were infused into the tail vein for three immunizations (0.5 mL each time), with a single infusion dose of 10 7 / Only;

[0181] Group 2: gp96-stimulated human T cells were infused into the tail vein for three immunizations (0.5 mL each time), with a single immunization dose of 10 7 Piece / piece;

[0182] In the above two groups, the tumor cells were infused three times on the 2nd, 3rd, and 4th days after inoculation. Starting from the first day of infusion, the tumor growth was observed every day, the tumor size was recorded, and the tumor volume was calculated according to the following formula: V = ab 2 / 2 (V—volume, a—long diameter of tumor, b—short diameter of tumor). Changes in tumor volume can be seen in Figure 7The results showed that CTLs induced by the three peptide-gp96 complexes could significantly inhibit the growth of liver cancer tumors.

[0183] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings that have been published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof. SEQUENCE LISTING <110> Foshan Rexiu Biotechnology Co., Ltd. <120> Epitope peptide of COL1A1 and complex of said epitope peptide and heat shock protein <130> IDC210136 <160> 7 <170> PatentIn version 3.5 <210> 1 <211> 9 <212> PRT <213> artificial <220> <223> Amino acid sequence of human COL1A1 polypeptide fragment 1 <400> 1 Gly Gln Asp Glu Asp Ile Pro Pro Ile 1 5 <210> 2 <211> 9 <212> PRT <213> artificial <220> <223> Amino acid sequence of human COL1A1 polypeptide fragment 2 <400> 2 Phe Val Asp Leu Arg Leu Leu Leu Leu 1 5 <210> 3 <211> 9 <212> PRT <213> artificial <220> <223> Amino acid sequence of human COL1A1 polypeptide fragment 3 <400> 3 Ala Gly Pro Pro Gly Phe Pro Gly Ala 1 5 <210> 4 <211> 25 <212> DNA <213> artificial <220> <223> gp96 amplification primer F1 sequence <400> 4 ggaattcatg gacgatgaag ttgat 25 <210> 5 <211> 29 <212> DNA <213> artificial <220> <223> gp96 amplification primer R1 sequence <400> 5 gctctagact attagaattc atctttttc 29 <210> 6 <211> 803 <212> PRT <213> artificial <220> <223> Amino acid sequence of human heat shock protein gp96 <400> 6 Met Arg Ala Leu Trp Val Leu Gly Leu Cys Cys Val Leu Leu Thr Phe 1 5 10 15 Gly Ser Val Arg Ala Asp Asp Glu Val Asp Val Asp Gly Thr Val Glu 20 25 30 Glu Asp Leu Gly Lys Ser Arg Glu Gly Ser Arg Thr Asp Asp Glu Val 35 40 45 Val Gln Arg Glu Glu Glu Ala Ile Gln Leu Asp Gly Leu Asn Ala Ser 50 55 60 Gln Ile Arg Glu Leu Arg Glu Lys Ser Glu Lys Phe Ala Phe Gln Ala 65 70 75 80 Glu Val Asn Arg Met Met Lys Leu Ile Ile Asn Ser Leu Tyr Lys Asn 85 90 95 Lys Glu Ile Phe Leu Arg Glu Leu Ile Ser Asn Ala Ser Asp Ala Leu 100 105 110 Asp Lys Ile Arg Leu Ile Ser Leu Thr Asp Glu Asn Ala Leu Ser Gly 115 120 125 Asn Glu Glu Leu Thr Val Lys Ile Lys Cys Asp Lys Glu Lys Asn Leu 130 135 140 Leu His Val Thr Asp Thr Gly Val Gly Met Thr Arg Glu Glu Leu Val 145 150 155 160 Lys Asn Leu Gly Thr Ile Ala Lys Ser Gly Thr Ser Glu Phe Leu Asn 165 170 175 Lys Met Thr Glu Ala Gln Glu Asp Gly Gln Ser Thr Ser Glu Leu Ile 180 185 190 Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Phe Leu Val Ala Asp Lys 195 200 205 Val Ile Val Thr Ser Lys His Asn Asn Asp Thr Gln His Ile Trp Glu 210 215 220 Ser Asp Ser Asn Glu Phe Ser Val Ile Ala Asp Pro Arg Gly Asn Thr 225 230 235 240 Leu Gly Arg Gly Thr Thr Ile Thr Leu Val Leu Lys Glu Glu Ala Ser 245 250 255 Asp Tyr Leu Glu Leu Asp Thr Ile Lys Asn Leu Val Lys Lys Tyr Ser 260 265 270 Gln Phe Ile Asn Phe Pro Ile Tyr Val Trp Ser Ser Lys Thr Glu Thr 275 280 285 Val Glu Glu Pro Met Glu Glu Glu Glu Ala Ala Lys Glu Glu Lys Glu 290 295 300 Glu Ser Asp Asp Glu Ala Ala Val Glu Glu Glu Glu Glu Glu Lys Lys 305 310 315 320 Pro Lys Thr Lys Lys Val Glu Lys Thr Val Trp Asp Trp Glu Leu Met 325 330 335 Asn Asp Ile Lys Pro Ile Trp Gln Arg Pro Ser Lys Glu Val Glu Glu 340 345 350 Asp Glu Tyr Lys Ala Phe Tyr Lys Ser Phe Ser Lys Glu Ser Asp Asp 355 360 365 Pro Met Ala Tyr Ile His Phe Thr Ala Glu Gly Glu Val Thr Phe Lys 370 375 380 Ser Ile Leu Phe Val Pro Thr Ser Ala Pro Arg Gly Leu Phe Asp Glu 385 390 395 400 Tyr Gly Ser Lys Lys Ser Asp Tyr Ile Lys Leu Tyr Val Arg Arg Val 405 410 415 Phe Ile Thr Asp Asp Phe His Asp Met Met Pro Lys Tyr Leu Asn Phe 420 425 430 Val Lys Gly Val Val Asp Ser Asp Asp Leu Pro Leu Asn Val Ser Arg 435 440 445 Glu Thr Leu Gln Gln His Lys Leu Leu Lys Val Ile Arg Lys Lys Leu 450 455 460 Val Arg Lys Thr Leu Asp Met Ile Lys Lys Ile Ala Asp Asp Lys Tyr 465 470 475 480 Asn Asp Thr Phe Trp Lys Glu Phe Gly Thr Asn Ile Lys Leu Gly Val 485 490 495 Ile Glu Asp His Ser Asn Arg Thr Arg Leu Ala Lys Leu Leu Arg Phe 500 505 510 Gln Ser Ser His His Pro Thr Asp Ile Thr Ser Leu Asp Gln Tyr Val 515 520 525 Glu Arg Met Lys Glu Lys Gln Asp Lys Ile Tyr Phe Met Ala Gly Ser 530 535 540 Ser Arg Lys Glu Ala Glu Ser Ser Pro Phe Val Glu Arg Leu Leu Lys 545 550 555 560 Lys Gly Tyr Glu Val Ile Tyr Leu Thr Glu Pro Val Asp Glu Tyr Cys 565 570 575 Ile Gln Ala Leu Pro Glu Phe Asp Gly Lys Arg Phe Gln Asn Val Ala 580 585 590 Lys Glu Gly Val Lys Phe Asp Glu Ser Glu Lys Thr Lys Glu Ser Arg 595 600 605 Glu Ala Val Glu Lys Glu Phe Glu Pro Leu Leu Asn Trp Met Lys Asp 610 615 620 Lys Ala Leu Lys Asp Lys Ile Glu Lys Ala Val Val Ser Gln Arg Leu 625 630 635 640 Thr Glu Ser Pro Cys Ala Leu Val Ala Ser Gln Tyr Gly Trp Ser Gly 645 650 655 Asn Met Glu Arg Ile Met Lys Ala Gln Ala Tyr Gln Thr Gly Lys Asp 660 665 670 Ile Ser Thr Asn Tyr Tyr Ala Ser Gln Lys Lys Thr Phe Glu Ile Asn 675 680 685 Pro Arg His Pro Leu Ile Arg Asp Met Leu Arg Arg Ile Lys Glu Asp 690 695 700 Glu Asp Asp Lys Thr Val Leu Asp Leu Ala Val Val Leu Phe Glu Thr 705 710 715 720 Ala Thr Leu Arg Ser Gly Tyr Leu Leu Pro Asp Thr Lys Ala Tyr Gly 725 730 735 Asp Arg Ile Glu Arg Met Leu Arg Leu Ser Leu Asn Ile Asp Pro Asp 740 745 750 Ala Lys Val Glu Glu Glu Pro Glu Glu Glu Pro Glu Glu Thr Ala Glu 755 760 765 Asp Thr Thr Glu Asp Thr Glu Gln Asp Glu Asp Glu Glu Met Asp Val 770 775 780 Gly Thr Asp Glu Glu Glu Glu Thr Ala Lys Glu Ser Thr Ala Glu Lys 785 790 795 800 Asp Glu Leu <210> 7 <211> 2412 <212> DNA <213> artificial <220> <223> Nucleotide sequence encoding human heat shock protein gp96 <400> 7 atgagggccc tgtgggtgct gggcctctgc tgcgtcctgc tgaccttcgg gtcggtcaga 60 gctgacgatg aagttgatgt ggatggtaca gtagagagg atctgggtaa aagtagagaa 120 ggatcaagga cggatgatga agtagtacag agaggaag aagctattca gttggatgga 180 ttaaatgcat cacaaataag agaacttaga gagaagtcgg aaaagtttgc cttccaagcc 240 gaagttaaca gaatgatgaa acttatcatc aattcattgt ataaaaataa agaattttc 300 ctgagagaac tgatttcaaa tgcttctgat gctttagata agataaggct aatatcactg 360 actgatgaaa atgctctttc tggaaatgag gaactaacag tcaaaattaa gtgtgataag 420 gagagaacc tgctgcatgt cacagacacc ggtgtaggaa tgaccagaga agagttggtt 480 aaaaaccttg gtaccatagc caaatctggg acaagcgagt ttttaaacaa aatgactgaa 540 gcacaggaag atggccagtc aacttctgaa ttgattggcc agtttggtgt cggtttctat 600 tccgcttcc ttgtagcaga taaggttatt gtcacttcaa aacacaacaa cgatacccag 660 cacatctggg agtctgactc caatgaattt tctgtaattg ctgacccaag aggaaacact 720 ctaggacggg gaacgacaat tacccttgtc ttaaaagaag aagcatctga ttaccttgaa 780 ttggatacaa ttaaaaatct cgtcaaaaaa tattcacagt tcataaactt tcctatttat 840 gtatggagca gcaagactga aactgttgag gagcccatgg aggaagaaga agcagccaaa 900 gaagagaaag aagaatctga tgatgaagct gcagtagagg aagaagaaga agaaaagaaa 960 ccaaagacta aaaaagttga aaaaactgtc tgggactggg aacttatgaa tgatatcaaa 1020 ccaatatggc agagaccatc aaaagaagta gaagaagatg aatacaaagc tttctacaaa 1080 tcattttcaa aggaaagtga tgaccccatg gcttatattc actttactgc tgaaggggaa 1140 gttaccttca aatcaatttt atttgtacc acatctgctc cacgtggtct gtttgacgaa 1200 tatggatcta aaaagagcga ttacattaag ctctatgtgc gccgtgtatt catcacagac 1260 gacttccatg atatgatgcc taatacctc aatttgtca agggtgtggt ggactcagat 1320 gatctcccct tgaatgtttc ccgcgagact cttcagcaac ataaactgct taaggtgatt 1380 aggaagaagc ttgttcgtaa aacgctggac atgatcaaga agattgctga tgataaatac 1440 aatgatactt tttggaaaga atttggtacc aacatcaagc ttggtgtgat tgaagaccac 1500 tcgaatcgaa cacgtcttgc taaacttctt aggttccagt cttctcatca tccaactgac 1560 attactagcc tagaccagta tgtggaaaga atgaaggaaa aacaagacaa aatctacttc 1620 atggctgggt ccagcagaaa agaggctgaa tcttctccat ttgttgagcg acttctgaaa 1680 aagggctatg aagttattta cctcacagaa cctgtggatg aatactgtat tcaggccctt 1740 cccgaatttg atgggaagag gttccagaat gttgccaagg aaggagtgaa gttcgatgaa 1800 agtgagaaaa ctaaggagag tcgtgaagca gttgagaaag aatttgagcc tctgctgaat 1860 tggatgaaag ataaagccct taggcaag attgaaaagg ctgtggtgtc tcagcgcctg 1920 agaatctc cgtgtgcttt ggtggccagc footcggat ggtctggcaa catggagaga 1980 atcatgaaag cacaagcgta ccaaacgggc aaagcatct ctacaaatta ctatgcgagt 2040 2100 2160 gcaacgcttc ggtcagggta tcttttacca gacactaaag catatggaga tagataagaa 2220 agaatgcttc gcctcagttt gaacattgac cctgatgcaa aggtggaaga agagcctgaa 2280 gaaacctg aagacagc agaagacaca acagagaca cagagcaaga cgaagtgaa 2340 gaaatggatg tgggaacaga tgaagaagaa gaacagcaa aggaatctac agctgaaaaa 2400 gatgaattgt aa 2412

Claims

1. A complex formed by a polypeptide composition and a heat shock protein gp96; wherein: The polypeptide composition comprises a polypeptide shown in SEQ ID NO: 1, a polypeptide shown in SEQ ID NO: 2 and a polypeptide shown in SEQ ID NO:

3.

2. The complex according to claim 1, wherein the complex is formed by the polypeptide composition and the heat shock protein gp96 by natural adsorption or heat shock.

3. The complex of claim 1, wherein the complex is prepared by mixing the polypeptide composition and heat shock protein gp96 in vitro. The composite according to claim 3 , wherein the mixing is performed at 40-80° C.

5. The complex of claim 3, wherein the complex is prepared by contacting the polypeptide composition with heat shock protein gp96 and placing the mixture at 55°C for 10 minutes and then at room temperature for 30 minutes. The complex according to claim 1 , wherein the heat shock protein gp96 has an amino acid sequence as shown in SEQ ID NO:

6.

7. The complex of claim 1, wherein the complex is prepared by mixing the polypeptide composition with heat shock protein gp96 in vitro at a mass ratio of 0.1:1 to 100:

1.

8. The complex according to claim 7, wherein The mass ratio is 0.1:1 to 50:1, 0.1:1 to 20:1, 0.1:1 to 10:1, 0.1:1 to 5:1, 0.1:1 to 1:1, 0.5:1 to 100:1, 0.5:1 to 50:1, 0.5:1 to 20:1, 0.5:1 to 10:1, 0.5:1 to 5:1, 0.5:1 to 1:1, 1:1 to 100:1, 1:1 to 50:1, 1:1 to 20:1, 1:1 to 10:1 or 1:1 to 5:

1.

9. A composition comprising at least two complexes according to any one of claims 1 to 8.

10. A method for preparing the complex according to any one of claims 1 to 8, comprising mixing the polypeptide composition with heat shock protein gp96.

11. The method according to claim 10, wherein the polypeptide composition forms a complex with the heat shock protein gp96 by natural adsorption or heat shock.

12. The method of claim 10, wherein the mixing is performed at 40-80°C.

13. The method of claim 10, comprising: The polypeptide composition and heat shock protein gp96 were contacted and placed at 55° C. for 10 minutes, and then placed at room temperature for 30 minutes.

14. The method of claim 10, wherein the heat shock protein gp96 has an amino acid sequence as shown in SEQ ID NO:

6.

15. The method of claim 10, comprising: The polypeptide composition is mixed with the heat shock protein gp96 in a mass ratio of 0.1:1 to 100:

1.

16. The method of claim 15, wherein: The mass ratio is 0.1:1 to 50:1, 0.1:1 to 20:1, 0.1:1 to 10:1, 0.1:1 to 5:1, 0.1:1 to 1:1, 0.5:1 to 100:1, 0.5:1 to 50:1, 0.5:1 to 20:1, 0.5:1 to 10:1, 0.5:1 to 5:1, 0.5:1 to 1:1, 1:1 to 100:1, 1:1 to 50:1, 1:1 to 20:1, 1:1 to 10:1 or 1:1 to 5:

1.

17. A method for preparing T cells, the method comprising stimulating immune cells using the complex according to any one of claims 1 to 8 or the composition according to claim 9; wherein, The T cell expresses a T cell receptor that can specifically recognize a polypeptide composition of COL1A1, wherein the polypeptide composition comprises a polypeptide shown in SEQ ID NO: 1, a polypeptide shown in SEQ ID NO: 2, and a polypeptide shown in SEQ ID NO:

3. The method of claim 17 , wherein the immune cells comprise PBMCs or T lymphocytes.

19. The method of claim 17, wherein the stimulation further comprises the use of an immunostimulatory cytokine.

20. A combination of isolated nucleic acid molecules comprising a nucleotide sequence encoding the complex of any one of claims 1-8.

21. A vector comprising a combination of isolated nucleic acid molecules according to claim 20.

22. The vector of claim 21, which is a viral vector.

23. The vector of claim 21, which is a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector or a baculoviral vector.

24. A host cell comprising a combination of isolated nucleic acid molecules according to claim 20 or a vector according to any one of claims 21-23.

25. A pharmaceutical composition comprising the complex of any one of claims 1-8, the composition of claim 9, the isolated nucleic acid molecule combination of claim 20, the vector of any one of claims 21-23 or the host cell of claim 24, and a pharmaceutically acceptable excipient.

26. The pharmaceutical composition of claim 25, which is a tumor vaccine.

27. The pharmaceutical composition of claim 25, comprising an adjuvant.

28. The pharmaceutical composition of claim 25, further comprising an additional therapeutic agent.

29. The pharmaceutical composition of claim 25, wherein the anti-tumor agent is selected from alkylating agents, mitotic inhibitors, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radionuclide agents, radiosensitizers, anti-angiogenic agents, cytokines, and immune checkpoint inhibitors.

30. The pharmaceutical composition of claim 29, wherein The immune checkpoint inhibitor is selected from PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody or TIM3 antibody.

31. Use of the complex of any one of claims 1 to 8 or the composition of claim 9 in the preparation of a medicament for inducing an immune response against a tumor expressing COL1A1 in a subject and / or preventing or treating a tumor expressing COL1A1 in a subject.

32. The use of claim 31, wherein the tumor expressing COL1A1 is selected from colorectal cancer, pancreatic cancer, gastric cancer, lung cancer, endometrial cancer, ovarian cancer, multiple myeloma, melanoma, thyroid cancer, bladder cancer, prostate cancer, breast cancer, head and neck cancer or acute myeloid leukemia.

33. The use of claim 31, wherein the T cells are from the subject.

34. The use of claim 33, wherein the subject is a human.

35. The use of claim 31, wherein the subject is HLA-A2 positive.

36. The use of claim 31, wherein the isolated polypeptide, polypeptide composition, composition or T cell is administered in combination with another therapeutic agent.

37. The use of claim 31, wherein the additional therapeutic agent is an immunostimulant or an anti-tumor agent.

38. The use according to claim 31, wherein the COL1A1 protein is abnormally expressed in the COL1A1-expressing tumor.

Citation Information

Patent Citations

  • Novel transporter constructs and transporter cargo conjugate molecules

    CN102256998A

  • Peptide fragment of gp96 protein and applications thereof

    CN102827257A

  • Application of human heat shock protein gp96 to prepare products screening hepatopathy

    CN104330570A

  • Novel application of I-type alpha 1 chain

    CN104651522A

  • Heat shock protein complex for breast cancer specificity and application of complex

    CN105175527A